Viewing Study NCT01855750

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:24 PM
Ignite Modification Date: 2026-01-25 @ 4:09 PM
Study NCT ID: NCT01855750
Status: COMPLETED
Last Update Posted: 2025-02-04
First Post: 2013-05-14
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Sponsor: Janssen Research & Development, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lymphoma View
None B-cell lymphoma View
None Non-germinal center B-cell subtype View
None Diffuse large B-cell lymphoma View
None Bruton's tyrosine kinase inhibitor View
None PCI-32765 View
None JNJ-54179060 View
None Ibrutinib View
None Rituximab View
None Cyclophosphamide View
None Doxorubicin View
None Vincristine View
None Prednisone View